Turning to individual securities, our new position in Santen Pharmaceutical (TSE:4536, Financial), a dominant player in the Japanese ophthalmic market, contributed to Fund performance. The company is growing its presence in the global ophthalmic space with solid growth in its China business through a recent acquisition. We built the position in Santen Pharmaceutical amid share price weakness in February and early March.
From Matthews Japan Fund (Trades, Portfolio)'s first-quarter 2020 commentary.
